Department of Renal Medicine, Singapore General Hospital, Academia Level 3, 20 College Road, Singapore, 169856, Singapore.
Duke-NUS Medical School, Programme in Health Services and Systems Research, Singapore, Singapore.
Int Urol Nephrol. 2023 Jan;55(1):191-200. doi: 10.1007/s11255-022-03299-x. Epub 2022 Jul 23.
Differentiating between diabetic kidney disease (DKD) and non-diabetic kidney disease (NDKD) in patients with Type 2 diabetes mellitus (T2DM) is important due to implications on treatment and prognosis. Clinical methods to accurately distinguish DKD from NDKD are lacking. We aimed to develop and validate a novel nomogram to predict DKD in patients with T2DM and proteinuric kidney disease to guide decision for kidney biopsy.
A hundred and two patients with Type 2 Diabetes Mellitus (T2DM) who underwent kidney biopsy from 1st January 2007 to 31st December 2016 were analysed. Univariate and multivariate analyses were performed to identify predictive variables and construct a nomogram. The discriminative ability of the nomogram was assessed by calculating the area under the receiver operating characteristic curve (AUROC), while calibration was assessed using the Hosmer-Lemeshow goodness-of-fit test and calibration plot. Internal validation of the nomogram was assessed using bootstrap resampling.
Duration of T2DM, HbA1c, absence of hematuria, presence of diabetic retinopathy and absence of positive systemic biomarkers were found to be independent predictors of DKD in multivariate analysis and were represented as a nomogram. The nomogram showed excellent discrimination, with a bootstrap-corrected C statistic of 0.886 (95% CI 0.815-0.956). Both the calibration curve and the Hosmer-Lemeshow goodness-of-fit test (p = 0.242) showed high degree of agreement between the prediction and actual outcome, with the bootstrap bias-corrected curve similarly indicating excellent calibration.
A novel nomogram incorporating 5 clinical parameters is useful in predicting DKD in type 2 diabetes mellitus patients with proteinuric kidney disease.
在 2 型糖尿病(T2DM)患者中,区分糖尿病肾脏疾病(DKD)和非糖尿病肾脏疾病(NDKD)很重要,因为这会影响治疗和预后。目前缺乏准确区分 DKD 和 NDKD 的临床方法。我们旨在开发和验证一种新的列线图,以预测 T2DM 合并蛋白尿性肾病患者的 DKD,从而指导进行肾活检。
分析了 2007 年 1 月 1 日至 2016 年 12 月 31 日期间接受肾活检的 102 名 2 型糖尿病(T2DM)患者。进行单因素和多因素分析以确定预测变量并构建列线图。通过计算接受者操作特征曲线(AUROC)下的面积来评估列线图的判别能力,通过 Hosmer-Lemeshow 拟合优度检验和校准图来评估校准。使用 bootstrap 重采样对内列线图进行验证。
多因素分析发现,T2DM 病程、HbA1c、无血尿、存在糖尿病视网膜病变和无阳性全身生物标志物是 DKD 的独立预测因素,并以列线图表示。该列线图具有出色的判别能力,bootstrap 校正的 C 统计量为 0.886(95%CI 0.815-0.956)。校准曲线和 Hosmer-Lemeshow 拟合优度检验(p=0.242)均显示预测结果与实际结果之间具有高度一致性,bootstrap 偏置校正曲线同样表明良好的校准。
一种新的纳入 5 个临床参数的列线图可用于预测 2 型糖尿病合并蛋白尿性肾病患者的 DKD。